IRIS
BAGNASCO, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.984
NA - Nord America 1.421
AS - Asia 1.259
Continente sconosciuto - Info sul continente non disponibili 278
SA - Sud America 120
AF - Africa 24
OC - Oceania 2
Totale 11.088
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.686
US - Stati Uniti d'America 1.323
SG - Singapore 422
CN - Cina 338
VN - Vietnam 221
BD - Bangladesh 139
FR - Francia 84
BR - Brasile 65
FI - Finlandia 55
DE - Germania 43
HK - Hong Kong 43
CA - Canada 41
AR - Argentina 28
GB - Regno Unito 23
RS - Serbia 23
JP - Giappone 18
NL - Olanda 18
MX - Messico 17
ID - Indonesia 14
IN - India 10
EC - Ecuador 8
IQ - Iraq 8
ES - Italia 7
IE - Irlanda 6
JM - Giamaica 6
TH - Thailandia 6
CO - Colombia 5
CR - Costa Rica 5
HN - Honduras 5
SA - Arabia Saudita 5
VE - Venezuela 5
ZA - Sudafrica 5
AT - Austria 4
CH - Svizzera 4
CL - Cile 4
GT - Guatemala 4
MA - Marocco 4
NP - Nepal 4
PL - Polonia 4
RU - Federazione Russa 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BG - Bulgaria 3
JO - Giordania 3
NI - Nicaragua 3
PE - Perù 3
PH - Filippine 3
PK - Pakistan 3
PR - Porto Rico 3
SN - Senegal 3
UZ - Uzbekistan 3
AU - Australia 2
AW - Aruba 2
BB - Barbados 2
BE - Belgio 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EG - Egitto 2
KE - Kenya 2
KZ - Kazakistan 2
MD - Moldavia 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
SE - Svezia 2
SV - El Salvador 2
TN - Tunisia 2
TR - Turchia 2
UA - Ucraina 2
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
OM - Oman 1
PS - Palestinian Territory 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
VG - Isole Vergini Britanniche 1
Totale 10.812
Salva come PNG Salva come JPEG
Città #
Genoa 3.052
Genova 2.913
Vado Ligure 733
Rapallo 675
San Jose 301
Ashburn 200
Singapore 174
Ho Chi Minh City 68
Hanoi 65
Council Bluffs 60
Lauterbourg 60
New York 59
Beijing 53
Helsinki 53
Hong Kong 40
Frankfurt am Main 36
Santa Clara 34
Milan 32
Bordighera 31
Belgrade 22
Los Angeles 22
Phoenix 22
Rome 21
Naples 18
Chicago 15
Bologna 14
Tokyo 14
Haiphong 13
Buffalo 12
Turin 12
Boardman 10
Amsterdam 9
Mexico City 9
Da Nang 8
Orem 8
Tampa 8
Atlanta 7
Brooklyn 7
Las Vegas 7
Miami 7
Dallas 6
Dublin 6
Montreal 6
Shanghai 6
Toronto 6
Biên Hòa 5
Brasília 5
Columbus 5
East Gwillimbury 5
London 5
Madrid 5
Newark 5
San José 5
The Bronx 5
Verona 5
Bergamo 4
Boston 4
Cagliari 4
Cleveland 4
Houston 4
Lancaster 4
Ninh Bình 4
Orlando 4
Tianjin 4
Trieste 4
Alexandria 3
Baku 3
Bangkok 3
Bari 3
Casalecchio di Reno 3
Cincinnati 3
City of London 3
Dakar 3
Dayton 3
Denver 3
Detroit 3
Guatemala City 3
Hải Dương 3
Jakarta 3
Kansas City 3
Lima 3
Managua 3
Milton 3
North Bergen 3
Oranjestad 3
Palermo 3
Paris 3
Piscataway 3
Queens 3
San Antonio 3
San Francisco 3
San Pedro Sula 3
São Paulo 3
Tashkent 3
Villa San Giovanni 3
Vĩnh Long 3
Zurich 3
Alpharetta 2
Angri 2
Aurora 2
Totale 9.126
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 355
Personalized medicine in allergy 218
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 214
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 203
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 202
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 201
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 200
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 198
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 195
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 192
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 188
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 182
Current insights in allergen immunotherapy 178
30 Years Of Sublingual Immunotherapy 177
Mepolizumab in severe asthma: evidence in real-life 176
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 175
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 174
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 172
Umeclidinium for the treatment of uncontrolled asthma 171
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 170
Biosimilars in allergic diseases 167
The safety of monoclonal antibodies in asthma 165
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 165
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 163
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 160
The path to personalized medicine in asthma 158
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab 153
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 151
Update on immunotherapy for the treatment of asthma 148
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 146
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 143
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 137
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 136
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 129
Biologicals for severe asthma: what we can learn from real-life experiences? 128
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 127
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 127
One year of mepolizumab. Efficacy and safety in real-life in Italy 127
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 127
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 117
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 115
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 114
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 111
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 111
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 110
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 107
Minimal clinically important difference for asthma endpoints: An expert consensus report 105
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 104
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 104
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 98
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 98
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 95
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 88
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 88
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 88
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report 87
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 87
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 86
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 86
Severe asthma: One disease and multiple definitions 86
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 77
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 77
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy 76
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 75
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 73
Specific Therapy for T2 Asthma 71
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 69
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 67
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 64
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 64
Background therapy in severe asthma on monoclonal antibody treatment in real life 63
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 61
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 61
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 59
SANI clinical remission definition: a useful tool in severe asthma management 58
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 58
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 57
Personalizing the approach to asthma treatment 57
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 56
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 53
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 50
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 50
null 49
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 48
Strategies to reduce corticosteroid-related adverse events in asthma 48
Biologics for the Treatments of Allergic Conditions: Severe Asthma 48
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 48
Real-life studies in allergen immunotherapy 44
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 43
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 41
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 38
Type 2 immunity in asthma 37
Small Airways: The “Silent Zone” of 2021 GINA Report? 32
Are there atypical sites of IgG4 related disease in head and neck region? Personal experience and literature review 30
The new indications for biologicals in type 2 diseases: perspectives 28
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? 28
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 28
Personalized medicine and allergen immunotherapy: the beginning of a new era? 27
Strategies to reduce corticosteroid-related adverse events in asthma 24
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 19
Totale 10.839
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.047
article - articoli 41.625
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.672
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022554 0 0 17 63 14 71 23 128 53 73 14 98
2022/2023814 66 74 6 67 86 126 53 37 141 53 90 15
2023/2024701 42 81 9 79 48 177 41 42 35 13 46 88
2024/20251.966 56 133 58 137 215 214 157 302 100 98 257 239
2025/20263.731 496 129 293 208 464 254 504 181 326 295 278 303
2026/2027807 318 179 310 0 0 0 0 0 0 0 0 0
Totale 11.088